Anna Saernefaelt | Global CMC Lead
CEPI

Anna Saernefaelt is a seasoned professional in the field of vaccine development and manufacturing, currently serving as Global Chemistry, Manufacturing, and Controls (CMC) Lead at the Coalition for Epidemic Preparedness Innovations (CEPI). With over 25 years of experience in the pharmaceutical and biotechnology industries, Anna has a proven track record of leading successful CMC strategies for vaccine development programs.

In her current role at CEPI, Anna is leading the Viral Vector Platform Program and plays a pivotal role in driving research, development, and strategic partnering initiatives for the global vaccine industry. She is responsible for overseeing the CMC aspects of vaccine projects, ensuring compliance with regulatory requirements, and optimizing manufacturing processes to accelerate vaccine development timelines.

Anna's expertise lies in bridging the gap between scientific innovation and regulatory compliance, enabling the timely delivery of safe and effective vaccines to address global health challenges. Her strong background in biopharmaceutical development, quality control, and project management equips her with the skills needed to navigate the complexities of the vaccine industry and drive impactful collaborations with key stakeholders.

As a speaker at the World Vaccine Congress Europe 2026, Anna brings valuable insights into the latest trends and advancements in vaccine research and development. Her contributions to the field have been instrumental in shaping the strategic direction of vaccine programs and fostering partnerships to enhance global vaccine preparedness.

With a passion for advancing public health through innovative vaccine technologies, Anna Saernefaelt is a respected leader in the global vaccine industry, dedicated to driving impactful change and improving access to life-saving vaccines worldwide.